imatinib mesylate has been researched along with Encapsulating Peritoneal Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrero, JJ; Deng, Y; Du, X; Li, L; Li, Z; Lin, H; Shen, N; Tang, Q; Wang, K; Wang, N; Wang, W; Wu, T | 1 |
| Arikan, H; Asicioglu, E; Filinte, D; Kaya, H; Koc, M; Ozener, C; Tuglular, S; Tugtepe, H; Velioglu, A; Yilmaz, N | 1 |
2 other study(ies) available for imatinib mesylate and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats.
Topics: Animals; Dialysis Solutions; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fucose; Fucosyltransferases; Glucose; Imatinib Mesylate; Male; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta1 | 2018 |
Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.
Topics: Animals; Benzamides; Chlorhexidine; Disease Models, Animal; Imatinib Mesylate; Immunohistochemistry; Male; Peritoneal Fibrosis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Transforming Growth Factor beta1 | 2013 |